ReviewCurrent opinion in infectious diseases2015
The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria.
Review in Current opinion in infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 89 citations in OpenAlex.
- High-risk clonal expansion of IMP-producingAntimicrobial agents and chemotherapy · 2025Article
- Comparative genomic study of blaScientific reports · 2025Article
- Lessons from Four Years (2021-2024) ofAntibiotics (Basel, Switzerland) · 2025Article
- Enhancing antimicrobial resistance surveillance and research: a systematic scoping review on the possibilities, yield and methods of data linkage studies.Antimicrobial resistance and infection control · 2025Article
- Combating antimicrobial resistance in Africa: a strategic roadmap for surveillance, stewardship, and research.Frontiers in cellular and infection microbiology · 2025Review
- A Decade-Long Review of the Virulence, Resistance, and Epidemiological Risks ofMicroorganisms · 2024Review
- Prevalence of carbapenem-resistantSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- An Overview of the Recent Advances in Antimicrobial Resistance.Microorganisms · 2024Review
- Integrated surveillance systems for antibiotic resistance in a One Health context: a scoping review.BMC public health · 2024Article
- Cas12a/Guide RNA-Based Platform for Rapidly and Accurately DetectingInfection and drug resistance · 2024Article
- Review
- What are the missing pieces needed to stop antibiotic resistance?Microbial biotechnology · 2023Review
- Cracking the Code: Unveiling the Diversity of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Molecular Dynamic Analysis of Carbapenem-ResistantMolecules (Basel, Switzerland) · 2023Article
- Resistance in Enterobacterales Is Higher Among People Living With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Exploiting genomics to mitigate the public health impact of antimicrobial resistance.Genome medicine · 2022Review
- Plethora of Resistance Genes in Carbapenem-Resistant Gram-Negative Bacteria in Greece: No End to a Continuous Genetic Evolution.Microorganisms · 2022Article
- Nationwide Surveillance and Molecular Characterization of Critically Drug-Resistant Gram-Negative Bacteria: Results of the Research University Network Thailand Study.Antimicrobial agents and chemotherapy · 2021Article
- An integrated surveillance network for antimicrobial resistance, India.Bulletin of the World Health Organization · 2021Article
- resistancebank.org, an open-access repository for surveys of antimicrobial resistance in animals.Scientific data · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewIt is widely accepted that infection control, advanced diagnostics, and novel therapeutics are crucial to mitigate the impact of antibiotic-resistant bacteria. The role of global, national, and regional surveillance systems as part of the response to the challenge posed by antibiotic resistance is not sufficiently highlighted. We provide an overview of contemporary surveillance programs, with emphasis on gram-negative bacteria. RECENT
findingsThe WHO and public health agencies in Europe and the United States recently published comprehensive surveillance reports. These highlight the emergence and dissemination of carbapenem-resistant Enterobacteriaceae and other multidrug-resistant gram-negative bacteria. In Israel, public health action to control carbapenem-resistant Enterobacteriaceae, especially Klebsiella pneumoniae carbapenemase producing K. pneumoniae, has advanced together with a better understanding of its epidemiology. Surveillance models adapted to the requirements and capacities of each country are in development. SUMMARY: Robust surveillance systems are essential to combat antibiotic resistance, and need to emphasize a 'one health' approach. Refinements in surveillance will come from advances in bioinformatics and genomics that permit the integration of global and local information about antibiotic consumption in humans and animals, molecular mechanisms of resistance, and bacterial genotyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.